Clinical review report : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6‐mercaptopurine (6‐MP) or who are intolerant to such therapies. Adalimumab (Humira) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Injections, Hypodermic.

Outcome assessment (Medical care).

Physical Description:

1 online resource (xi, 72 pages)

Place of Publication:

Ottawa (ON) : CADTH, 2016.

Summary:

The objective of this report is to perform a systematic review of the beneficial and harmful effects of adalimumab via subcutaneous injection at recommended doses for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy or who are intolerant to such therapies.

Contents:

Abbreviations

Executive Summary

1. Introduction

1.1. Disease prevalence and incidence

1.2. Standards of therapy

1.3. Drug

2. Objectives and Methods

2.1. Objectives

2.2. Methods

3. Results

3.1. Findings from the literature

3.2. Included studies

3.3. Patient disposition

3.4. Exposure to study treatments

3.5. Critical appraisal

3.6. Efficacy

3.7. Harms

4. Discussion

4.1. Summary of available evidence

4.2. Interpretation of results

4.3. Potential place in therapy

5. Conclusions

APPENDIX 1. Patient Input Summary

APPENDIX 2. Literature Search Strategy

APPENDIX 3. Excluded Studies

APPENDIX 4. Detailed Outcome Data

APPENDIX 5. Validity of Outcome Measures

APPENDIX 6. Summary of Other Studies

APPENDIX 7. Summary of Indirect Comparisons

References.

Notes:

Description based on publisher supplied metadata and other sources.